These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 28387984

  • 21. Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.
    Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M.
    Nephrology (Carlton); 2016 Mar; 21(3):261-5. PubMed ID: 26818219
    [Abstract] [Full Text] [Related]

  • 22. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
    Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J.
    Nephrol Dial Transplant; 2020 Dec 04; 35(12):2147-2153. PubMed ID: 31411695
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.
    Transfus Apher Sci; 2016 Dec 04; 55(3):357-362. PubMed ID: 27742267
    [Abstract] [Full Text] [Related]

  • 24. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.
    Servais A, Devillard N, Frémeaux-Bacchi V, Hummel A, Salomon L, Contin-Bordes C, Gomer H, Legendre C, Delmas Y.
    Nephrol Dial Transplant; 2016 Dec 04; 31(12):2122-2130. PubMed ID: 27587606
    [Abstract] [Full Text] [Related]

  • 25. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience.
    Sheerin NS, Kavanagh D, Goodship TH, Johnson S.
    QJM; 2016 Jan 04; 109(1):27-33. PubMed ID: 25899302
    [Abstract] [Full Text] [Related]

  • 26. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.
    Gately R, San A, Kurtkoti J, Parnham A.
    Nephrology (Carlton); 2017 Feb 04; 22 Suppl 1():32-35. PubMed ID: 28176475
    [Abstract] [Full Text] [Related]

  • 27. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.
    Pediatr Nephrol; 2019 Nov 04; 34(11):2261-2277. PubMed ID: 30402748
    [Abstract] [Full Text] [Related]

  • 28. Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.
    Chua J, Paizis K, He SZ, Mount P.
    Nephrology (Carlton); 2017 Feb 04; 22 Suppl 1():18-22. PubMed ID: 28176472
    [Abstract] [Full Text] [Related]

  • 29. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.
    Nefrologia; 2015 Feb 04; 35(5):421-47. PubMed ID: 26456110
    [Abstract] [Full Text] [Related]

  • 30. Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.
    Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Brüggemann RJ, Wetzels J, van de Kar N, van den Heuvel L.
    Clin Pharmacol Ther; 2017 Oct 04; 102(4):671-678. PubMed ID: 28295239
    [Abstract] [Full Text] [Related]

  • 31. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.
    Ariceta G.
    Pediatr Nephrol; 2019 May 04; 34(5):943-949. PubMed ID: 30693384
    [No Abstract] [Full Text] [Related]

  • 32. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
    de Ville de Goyet M, Detaille T, Godefroid N.
    J Pediatr Hematol Oncol; 2019 Oct 04; 41(7):e459-e462. PubMed ID: 30933023
    [Abstract] [Full Text] [Related]

  • 33. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
    Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC.
    Neth J Med; 2012 Apr 04; 70(3):121-9. PubMed ID: 22516576
    [Abstract] [Full Text] [Related]

  • 34. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.
    Am J Kidney Dis; 2019 Jul 04; 74(1):56-72. PubMed ID: 30851964
    [Abstract] [Full Text] [Related]

  • 35. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M, Leite BN, Ferreiro T, Calvo M, Fernández C, Alonso Á, Rodriguez A, Salvador P, Seijo R, Pita S, Arjona E, Rodríguez de Córdoba S, Valdés Cañedo F.
    Am J Nephrol; 2018 Jul 04; 48(3):225-233. PubMed ID: 30205388
    [Abstract] [Full Text] [Related]

  • 36. Treatment and management of children with haemolytic uraemic syndrome.
    Walsh PR, Johnson S.
    Arch Dis Child; 2018 Mar 04; 103(3):285-291. PubMed ID: 28899876
    [Abstract] [Full Text] [Related]

  • 37. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
    Bamhraz AA, Rahim KA, Faqeehi HY, Alanazi A.
    Kidney Blood Press Res; 2020 Mar 04; 45(6):939-954. PubMed ID: 33238263
    [Abstract] [Full Text] [Related]

  • 38. Ravulizumab facilitates reduced burden of vascular access, a major benefit in paediatric atypical haemolytic uraemic syndrome.
    Bleathman F, Kausman JY, Hosking LM, Forbes TA.
    J Paediatr Child Health; 2024 Jun 04; 60(6):183-187. PubMed ID: 38661088
    [Abstract] [Full Text] [Related]

  • 39. An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
    Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V, HUS International.
    Pediatr Nephrol; 2016 Jan 04; 31(1):15-39. PubMed ID: 25859752
    [Abstract] [Full Text] [Related]

  • 40. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.
    Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):635-645. PubMed ID: 29106598
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.